LivaNova is executing a successful turnaround, evidenced by accelerating revenue growth of 10.8% YoY in 2026Q2 and gross margin expansion to 70.1%, the highest in the reported period. The company has significantly deleveraged, reducing total debt by 48% from $...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $1.26+15.6% vs $1.09 | $391M+2.7% vs $381M |
Q2 2026 May 6, 2026 | $0.98+15.3% vs $0.85 | $362M+4.7% vs $346M |
Q1 2026 Feb 25, 2026 | $0.86+7.5% vs $0.80 | $361M+2.1% vs $353M |
Q4 2025 Nov 5, 2025 | $1.11+20.8% vs $0.92 | $358M+4.4% vs $343M |
Squarepoint Ops LLC acquired a new position in shares of LivaNova PLC (NASDAQ: LIVN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 17,242 shares of the company's stock, valued at approximately $1,418,000. Several other institutional investors and hedge
LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director's equity stake held directly before the filing.
Bank of America Corp DE cut its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 30.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 533,017 shares of the company's stock after selling 235,233 shares during the quarter. Bank of America Corp
Benchmark LIVN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for LivaNova PLC (LIVN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $78.49 | $4.31B | -17.64 | 10.74% | -17.47% | -19.24% | — | |
| $16.67 | $1.93B | -13.66 | 8.28% | -21.25% | -44% | — | |
| $20.98 | $1.55B | 6.36 | 18.52% | 80.56% | 30.03% | — | |
| $159.86 | $9.43B | -48.74 | 32.33% | -30.68% | -27.07% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — | |
| $103.73 | $180.68B | 27.88 | 5.67% | 13.91% | 12.09% | — |
LivaNova PLC (LIVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
LivaNova PLC (LIVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 11, 2026·SEC
May 6, 2026·SEC
Get notified when LIVN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LivaNova PLC (LIVN) stock FAQ — growth, dividends, profitability & financials explained
LivaNova PLC (LIVN) reported $1.47B in revenue for fiscal year 2025. This represents a 147051% increase from $1.0M in 1995.
LivaNova PLC (LIVN) grew revenue by 10.7% over the past year. This is steady growth.
Yes, LivaNova PLC (LIVN) is profitable, generating $188.6M in net income for fiscal year 2025 (-17.5% net margin).
LivaNova PLC (LIVN) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.
LivaNova PLC (LIVN) generated $148.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
